Creative Biolabs is a lead scientific service provider in oncology immunotherapy discovery and development and is recognized as one of the most reliable partners by clients all over the world. Creative Biolabs has developed the B cell engineering platform to deliver therapeutic proteins to the tumor using differentiated B cells as a novel therapy for oncology.
Engineered B cell is a potential technique for tumor treatment by expressing and carrying therapeutic proteins to the target site. To make it a long-lived delivery cell like plasma cells that can live in the bone marrow microenvironment for decades and secrete high-affinity antigen-specific antibodies to combat pathogens. One of the approaches is to guide B cell lineage transit to the plasma cell, as the plasma cell is one of the terminally differentiated cells of B cells and may be acquired by multiple approaches recapitulating the B cell differentiation process in vivo.
Creative Biolabs is specialized in guiding B cell differentiation to protein-secreting plasma cells using advanced methods and approaches.
Our robust platform covers the entire stages, including B cell engineering technique discovery, therapeutic protein delivery, engineered B cell assessment, and differentiation service. Our plasma cell differentiation services include:
Our innovative combination of protein medicine synthesis for oncology therapy and B cell differentiation makes us the best partner to support your engineered B cell discovery study. If the following methods do not what you intend, please contact us immediately and tell us your needs and our expert will plan an appropriate strategy for your idea.
B cell-extrinsic microenvironment-derived signals, such as cytokines and ligands from Tfh cells, and chemokines, can interact with activated B cells and affect the differentiation process within the follicle foci.
Creative Biolabs has developed an optimized in vitro differentiating system by recapitulating signals from cell stimuli in vivo. Or the unique transition process can be accomplished in animals in vivo.
Long-lived, protein-secreting plasma cells differentiated from B cells are potential oncology therapy for disease treatment.
Creative Biolabs provides an advanced differentiation method based on the B cell-intrinsic gene expression system regulated by transcription factors, transiting B cells to terminated plasma cells with the improved property.
We are dedicated to engineered B cell differentiation services, which is a robust approach for long-lived plasma cell products for oncology therapy. Equipped with advanced technology and cutting-edge expertise, Creative Biolabs is a reliable service provider with full competence in engineering B cells for immunotherapy. We worked closely with our clients and provide end-to-end service with a fast turnaround. Please contact us for further discussion.